Heart disease is still the leading cause of death worldwide, and the biology behind it unfolds over decades — quietly, long before any symptom. That makes it one of the most important levers in longevity: the slow accumulation of cholesterol in artery walls is a process you can measure and act on years ahead of time. The catch is that the number most people are handed at a check-up — LDL cholesterol — may not be the number that best captures their risk.
A growing body of evidence points to a different marker as the more honest one: apolipoprotein B, usually shortened to ApoB. This article explains what ApoB is, why it tracks cardiovascular ageing more faithfully than standard cholesterol, what nudges it up or down, and how to read your own result. It is educational, not medical advice — for any decision about your own treatment, see the medical disclaimer and speak to a clinician.
What ApoB actually measures
Cholesterol does not float freely in your blood — it is ferried around inside particles called lipoproteins. The ones that drive artery disease (LDL, VLDL, IDL and lipoprotein(a)) are described as atherogenic, meaning artery-damaging. Here is the key fact: every one of these particles carries exactly one molecule of apolipoprotein B on its surface. So measuring ApoB is, in effect, a direct head-count of every atherogenic particle in your bloodstream (Sniderman et al., 2019).
That distinction matters because a standard lipid panel reports LDL cholesterol — the mass of cholesterol cargo carried inside LDL particles — not the number of particles. And the amount of cholesterol packed into each particle varies a lot from person to person. Two people can have an identical LDL-cholesterol reading while one is carrying far more particles than the other, each one a separate opportunity to lodge in an artery wall. ApoB sees that difference; LDL cholesterol does not (Sniderman et al., 2019).
The mechanism of atherosclerosis explains why particle number is what counts. Cholesterol can only enter the artery wall while it is packaged inside an ApoB-bearing particle. Once a particle slips into the wall and is trapped, it deposits its cargo and seeds the plaque that narrows arteries over a lifetime. The more particles circulating, the more get trapped — so the burden of disease tracks the count of ApoB particles more tightly than the total cholesterol mass they happen to be carrying (Sniderman et al., 2019).
Why it predicts cardiovascular ageing better than LDL
This is not just elegant theory; the discordance has been tested in large populations. When LDL cholesterol and ApoB disagree — when one is "normal" but the other is high — researchers can see which one the body actually listens to.
In a study of more than 13,000 statin-treated people from the Copenhagen General Population Study followed for a median of eight years, those whose ApoB was high while their LDL cholesterol looked low still carried a meaningfully raised risk of heart attack and of death from any cause. The reverse pattern — high LDL cholesterol but low ApoB — was not associated with extra risk. In other words, when the two markers part ways, ApoB is the one that calls the outcome correctly (Johannesen et al., 2021).
Genetic studies strengthen the case for causation rather than mere correlation. Using Mendelian randomisation — which leans on naturally randomised gene variants to mimic a lifelong trial — researchers analysing the UK Biobank found that when LDL cholesterol, triglycerides and ApoB were modelled together, only ApoB retained a robust independent association with coronary heart disease; the apparent effect of LDL cholesterol reversed once ApoB was accounted for. Their conclusion was blunt: ApoB is the predominant trait explaining how blood lipids cause heart disease (Richardson et al., 2020).
A separate analysis pooling the UK Biobank with two major statin trials (FOURIER and IMPROVE-IT) reached the same place from a different angle. Across both people without prior heart disease and patients already on statins, the risk of heart attack was best captured by the number of ApoB particles — independent of how much cholesterol or triglyceride each particle carried. The authors framed ApoB as plausibly the primary driver of atherosclerosis, and the logical target of lipid-lowering strategies (Marston et al., 2022).
For longevity, the implication is practical. Because atherosclerosis is cumulative — particle-years of exposure, much like pack-years of smoking — a marker that counts particles is a better gauge of how fast your arteries are ageing than one that estimates cargo. A reassuring LDL number can mask a high particle count, especially in people with high triglycerides, type 2 diabetes, metabolic syndrome or insulin resistance, where particles tend to be small and cholesterol-depleted (Marston et al., 2022; Johannesen et al., 2021).
One marker that catches a hidden risk: Lp(a)
ApoB has a useful side-effect: it partly captures lipoprotein(a), an inherited particle that also carries one ApoB molecule. Lp(a) is worth knowing about because, particle for particle, a genetic analysis estimated it to be roughly six-fold more atherogenic than ordinary LDL (Björnson et al., 2024). ApoB does not replace a dedicated Lp(a) test, but a high ApoB that is hard to explain from the rest of a lipid panel can be a prompt to look further.
What raises and lowers ApoB
ApoB reflects the total traffic of atherogenic particles, so the same factors that influence those particles move the number. The evidence below describes what studies have observed in populations — it is general education, not a personal prescription, and none of it should be used to start or stop any medication.
What tends to push ApoB up:
- Diets high in saturated fat. Saturated fat raises LDL-particle production. Pooled evidence from randomised controlled trials finds that replacing dietary saturated fat with polyunsaturated fat lowers LDL cholesterol and the apolipoprotein-B-bearing particles that carry it (Wu et al., 2019).
- Excess body fat, particularly visceral fat, and insulin resistance. These states increase the liver's output of triglyceride-rich VLDL particles, raising the particle count — and often producing the "small, dense" LDL pattern in which LDL cholesterol underestimates ApoB (Marston et al., 2022).
- Inherited factors. Some people produce more atherogenic particles for genetic reasons, including familial hypercholesterolaemia and high Lp(a) (Björnson et al., 2024).
What tends to bring ApoB down:
- Swapping saturated fat for unsaturated fat. Replacing saturated with unsaturated fat is among the most consistently observed dietary effects on atherogenic lipoproteins in randomised trials (Wu et al., 2019).
- Soluble fibre, weight loss and improved insulin sensitivity reduce particle production — the same mechanisms that improve a fasting HbA1c, which is why metabolic and cardiovascular health move together.
- Lipid-lowering therapy, where clinically indicated, lowers ApoB by reducing the number of circulating particles. Decisions about any such treatment belong with your doctor.
A point worth holding onto: large genetic and trial datasets are consistent with the idea that lowering the number of ApoB particles is what reduces risk, rather than chasing any single lipid sub-fraction (Marston et al., 2022; Richardson et al., 2020).
How to read your ApoB result
ApoB is reported in grams per litre (g/L). As a general orientation rather than a treatment threshold:
- Below ~1.0 g/L is broadly considered favourable for the general population, with some longevity-minded clinicians aiming lower still in people at higher risk.
- Around 1.0–1.2 g/L sits in a grey zone where the rest of your risk picture — blood pressure, HbA1c, family history, Lp(a), smoking — matters.
- Above ~1.2 g/L generally warrants a conversation with a clinician, especially alongside a family history of early heart disease.
These bands are a starting point for understanding, not a diagnosis. Optimal targets differ by individual risk, and your laboratory's reference range and clinical context always take precedence. The single most useful habit is to interpret ApoB in the round — next to your other markers and your personal history — and to track the trend over time rather than over-reading one snapshot. A clinician should guide any action you take.
Why this belongs in a longevity check
If you want one number that summarises how hard your arteries are working against a lifetime of particle exposure, ApoB is among the strongest candidates the evidence currently supports (Sniderman et al., 2019; Marston et al., 2022). It is most powerful when read alongside the rest of your metabolic and cardiovascular picture — which is exactly the point of a comprehensive panel rather than a single isolated test. Knowing your ApoB early, while you can still influence the trajectory, is precisely the kind of measure-then-act approach that healthspan depends on.
You can read more about the biomarker itself, including UK reference ranges and what high and low results mean, on our apolipoprotein B page.
Check your Apolipoprotein B (ApoB) with BioAge Complete.
Sources
According to PubMed:
- Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 2019;4(12):1287–1295. PMID: 31642874. DOI
- Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology. 2021;77(11):1439–1450. PMID: 33736827. DOI
- Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, Holmes MV. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Medicine. 2020;17(3):e1003062. PMID: 32203549. DOI
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology. 2022;7(3):250–256. PMID: 34773460. DOI
- Björnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, Borén J. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. Journal of the American College of Cardiology. 2024;83(3):385–395. PMID: 38233012. DOI
- Wu JHY, Micha R, Mozaffarian D. Dietary fats and cardiometabolic disease: mechanisms and effects on risk factors and outcomes. Nature Reviews Cardiology. 2019;16(10):581–601. PMID: 31097791. DOI
This article is for education only and is not medical advice. See our medical disclaimer.
